BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
Author:
Affiliation:
1. Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia
2. Ludwig Institute for Cancer Research, Austin Branch, Victoria, Australia
3. Peter MacCallum Cancer Centre, Victoria, Australia
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference11 articles.
1. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
2. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
3. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
4. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development of a potent small‐molecule degrader against oncogenic BRAF V600E protein that evades paradoxical MAPK activation;Cancer Science;2022-06-05
2. The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma;Cancers;2021-05-07
3. Is hyperprogressive disease a specific phenomenom of immunotherapy?;Exploration of Targeted Anti-tumor Therapy;2020-12-28
4. Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors;Frontiers in Oncology;2020-09-11
5. The Emerging Role of Ras Pathway Signaling in Pediatric Cancer;Cancer Research;2020-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3